Psychiatr. pro Praxi, 2006; 3: 128-130

New treatment possibilities for bipolar depression

prof. MUDr. Eva Češková CSc
Psychiatrická klinika LF MU a FN Brno

At first general principles of treatment of bipolar disorder are summarized. Further the paper is dealing with the treatment of bipolar depression. In this indication the treatment with atypical antipsychotics is becoming a point of interest. Recently, two double-blind, randomized placebo-controlled studies in patients with bipolar depression comparing olanzapine and combination of olanzapine and fluoxetine with placebo and quetiapine with placebo were published. Quetiapine monotherapy at doses of 300 and 600 mg pro die demonstrated statistically significant improvement in all scales evaluating depressive and anxiety symptomatology, quality of sleep and quality of life compared with placebo from week 1 onward and was well tolerated.

Keywords: bipolar depression, the 2nd generation of antipsychotics, quetiapine, olanzapine

Published: July 1, 2006  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Češková E. New treatment possibilities for bipolar depression. Psychiatr. praxi. 2006;7(3):128-130.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. American Psychiatric Association Practice Guidelines: Practice guideline for the treatment of patients with bipolar disorder (revision). Am J Psychiatry 2002; 159 (Suppl.4): 2-50.
    2. Calabrese JR, Keck PE Jr, MacFadden W et al. A randomized, double-blind, placebo-controlled trial of quetiapine in the treatment of bipolar I or II depression. Am J Psychiatry 2005; 162: 1351-1360. Go to original source... Go to PubMed...
    3. Češková E, Kašpárek T. Kdy je polyfarmakoterapie léčbou první nebo druhé volby? II. část. Čes. a slov. Psychiatrie 2003; 99: 189-193.
    4. Češková E, Kašpárek T. Léčba bipolární deprese. Čes. a slov. Psychiatrie 2004; 100: 229-237.
    5. Češková E. Schizofrenie a její léčba. Praha, Maxdorf, 2005.
    6. Grof P. Selecting effective long-term treatment for bipolar patients: monotherapy and combinations. J Clin Psychiatry. 2003; 64 (suppl 5): 53-61.
    7. Grunze H, Kasper S, Goodwin G, Bowden C et al. World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of bipolar disorder. Part I.: treatment of bipolar depression. World J Biol Psychiatry 2002; 3: 115-124. Go to original source... Go to PubMed...
    8. Herman E, Grof P, Hovorka J et al. Bipolární porucha v: Postupy v léčbě psychických poruch (Eds. Seifertová D, Praško J, Hoschl C.) Amepra, 2002, 94-126.
    9. Möller HJ. State of the art of drug treatment of schizophrenia and the future position of the novel/atypical antipychotics. World J Biol Psychiatry 2000; 1: 204-214. Go to original source... Go to PubMed...
    10. Rihmer Z, Pestality P. Bipolar II disorder and suicidal behaviour. Psychiatr Clin North Am 1999; 22: 667-673. Go to original source... Go to PubMed...
    11. Suppes T, Dennehy EB. Evidence-based long-term treatment of bipolar II disorder. J Clin Psychiatry 2002; 63 (suppl 10): 29-30.
    12. Tohen M, Vieta E, Calabrese J et al.: Efficacy of olanzapine and olanzapine-fluoxetine combination in the treatment of bipolar I depression. Arch Gen Psychiatry 2003; 60: 1079-1088. Go to original source... Go to PubMed...

    Return to the content


    Psychiatry for Practice

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.